Skip to main content
Fig. 3 | Cancer Cell International

Fig. 3

From: Conjoint analysis of circulating tumor cells and solid tumors for exploring potential prognostic markers and constructing a robust novel predictive signature for breast cancer

Fig. 3

GARS is an oncogene for breast cancer. A The expression of GARS in breast cancer, tumor-adjacent tissues, and normal tissues from the GTEx and TCGA datasets. B Validation of GARS knockdown efficacy in breast cancer cell lines by Western blot. C Cell proliferation capacity was examined in control and GARS knockdown cell lines by CCK-8 assay. D A colony formation assay was carried out to evaluate the proliferation abilities of breast cancer cells in control and GARS knockdown conditions. Cell migration assay (E) and invasion assay (F) for HS-578T cells and MDA-MB-231 LM2 in control and GARS knockdown conditions. G GSEA found that mTOR signaling pathway genes were enriched in the high GARS expression group. H Western blot analysis of AKT-mTOR signaling pathway proteins in control or GARS knockdown cells. I KEGG analysis of the most positively related genes of GARS. J Cell cycle analysis was performed with flow cytometry in cells (control or GARS knockdown cells) after release at the same time. K Western blot analysis of cell cycle-related proteins in control or GARS knockdown cells

Back to article page

Cancer Cell International

ISSN: 1475-2867

Contact us